Market Research Logo

Insulin Resistance - Pipeline Review, H1 2015

Introduction
Global Markets Direct Report Coverage
Insulin Resistance Overview
Therapeutics Development
Pipeline Products for Insulin Resistance - Overview
Pipeline Products for Insulin Resistance - Comparative Analysis
Insulin Resistance - Therapeutics under Development by Companies
Insulin Resistance - Therapeutics under Investigation by Universities/Institutes
Insulin Resistance - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Insulin Resistance - Products under Development by Companies
Insulin Resistance - Products under Investigation by Universities/Institutes
Insulin Resistance - Companies Involved in Therapeutics Development
AUS Bio Limited
Genfit SA
GlaxoSmithKline plc
Hadasit Medical Research Services & Development Ltd
Mertiva AB
Mochida Pharmaceutical Co., Ltd.
Novartis AG
Prometheon Pharma, LLC
Sanofi
Thetis Pharmaceuticals LLC
Insulin Resistance - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
6860766 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVS-857 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Englerin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GFT-505 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MD-960 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-Catalase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide for Obesity and Insulin Resistance - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-088 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SERX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Hypertension and Insulin Resistance - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insulin Resistance - Recent Pipeline Updates
Insulin Resistance - Dormant Projects
Insulin Resistance - Product Development Milestones
Featured News & Press Releases
Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Insulin Resistance, H1 2015
Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Insulin Resistance - Pipeline by AUS Bio Limited, H1 2015
Insulin Resistance - Pipeline by Genfit SA, H1 2015
Insulin Resistance - Pipeline by GlaxoSmithKline plc, H1 2015
Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015
Insulin Resistance - Pipeline by Mertiva AB, H1 2015
Insulin Resistance - Pipeline by Mochida Pharmaceutical Co., Ltd., H1 2015
Insulin Resistance - Pipeline by Novartis AG, H1 2015
Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H1 2015
Insulin Resistance - Pipeline by Sanofi, H1 2015
Insulin Resistance - Pipeline by Thetis Pharmaceuticals LLC, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Insulin Resistance Therapeutics - Recent Pipeline Updates, H1 2015
Insulin Resistance - Dormant Projects, H1 2015
List of Figures
Number of Products under Development for Insulin Resistance, H1 2015
Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Insulin Resistance - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Insulin Resistance - Pipeline Review, H1 2015’, provides an overview of the Insulin Resistance’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Insulin Resistance
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;